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Abstract 1 
Objectives: Pressure injuries (PIs) are one of the most common types of complex wounds and 2 
impose a huge economic burden to the healthcare system and the patients. A plethora of topical 3 
treatments is widely available for PI treatment, yet there is a paucity of evidence with regards to the 4 
most effective treatment. The objective of this study was to compare the effect of various topical 5 
treatments and identify the best treatment choice(s) for PI healing.  6 
Design: Systematic review and network meta-analysis. 7 
Setting and Participants: All published randomized controlled trials that compared the 8 
effectiveness of two or more of the following dressing groups: basic, foam, active, hydroactive, and 9 
other wound dressings.  10 
Measures: The outcome was the relative risk (RR) of complete healing following treatment and the 11 
generalised pair-wise modelling framework was used to generate mixed treatment effects against 12 
hydroactive wound dressing, currently the standard of treatment for PIs. All treatments were then 13 
ranked by their point estimates. 14 
Results: 40 studies (1,757 participants) comparing 5 dressing groups were included in the analysis. 15 
All dressings groups ranked better than basic (i.e. saline gauze or similar inert dressing). The foam 16 
(RR 1.18; 95%CI 0.95-1.48) and active wound dressing (RR 1.16; 95%CI 0.92-1.47) ranked better 17 
than hydroactive wound dressing in terms of healing of PIs when the latter was used as the 18 
reference group.   19 
Conclusions/Implications: There was substantial uncertainty around the point estimates; however, 20 
evidence from our analysis supports the use of hydroactive wound dressings to replace basic 21 
dressings. Foam and active wound dressing groups seem promising and therefore need further 22 
investigation. High-quality, rigorously conducted research about the clinical effectiveness of the 23 
topical treatments in these two groups developed in consultation with health professionals, patients, 24 
and their carers is needed to identify if indeed foam and active wound dressings provide advantages 25 
over hydroactive dressings.   26 
*Manuscript
Click here to view linked References
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Introduction 27 
Pressure injuries (PI),
1
 also known as pressure ulcers or bed-sores, are wounds involving the 28 
skin and sometimes the tissue on bony parts of the body, often occurring over bony prominences such 29 
as the sacrum and heel.
2
 They are caused by a combination of pressure, shear, and friction that leads 30 
to microcirculatory occlusion, resulting in stimulation of inflammatory processes.
2
 This in turn can 31 
lead to cell death, ulceration, and tissue necrosis.
3
 PIs can have a significant impact on those 32 
affected, as they can cause pain and infection which can increase patient’s hospital length of stay 33 
and significantly decrease their health-related quality of life.
4
 People at high risk of developing PIs 34 
include those with limited mobility such as older people, people with short or long-term medical 35 
conditions, and those with spinal injuries.
5
 Lack of mobility, reduced sensory perception, poor 36 
nutrition, and hydration as well as lack of blood flow can all increase the risk of developing PIs.
5
 37 
Development of PI can be rapid and lead to irreversible tissue damage in vulnerable patients after as 38 
little as 30 minutes of uninterrupted pressure.
6
 39 
Globally, PIs are one of the most common types of complex wounds. An estimated 2.5 40 
million people are affected annually in the US alone.
7
 A large European pilot study estimated the 41 
hospital PI point prevalence to be 10.5%.
8
 National PI data collected in the UK’s National Health 42 
Service (NHS) reported a prevalence of 4.2% across community and acute care settings in 43 
September 2017,
9
 although the study could have underestimated the actual prevalence of PIs in the 44 
UK due to the low sensitivity of the tool used to identify the cases.
10,11
 Prevalence of PIs can vary 45 
according to setting and can be as high as 26% in some settings such as long-term, acute-care, and 46 
rehabilitation settings.
12
  47 
Managing PIs can be expensive. Annual health care costs associated with PIs in the UK in 48 
2012/13 were estimated to be in the range GBP 4.5 to 5.1 billion.
13
 In the USA in 2014 alone, 49 
treatment for PIs were estimated at USD 9.1 to 11.6 billion annually with 2.5 million people 50 
affected and approximately 60,000 deaths resulting from PIs.
14
 The total costs to the Australian 51 
healthcare system for treating PIs have been estimated at AUD 1.8 billion  annually or 9% of public 52 
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hospital expenditure.
15
 Although dated, these cost-estimates provide an insight about the substantial 53 
financial burden PIs represent within contemporary health contexts. 54 
In terms of the treatment of PIs, there are two major strategies that are currently being 55 
employed: 1) the use of pressure-relieving support surfaces (e.g. alternating pressure air mattresses); 56 
and 2) management of ulcers using topical treatments such as wound dressings.
16,17
 Other general 57 
strategies for treating and healing PIs include optimizing circulation/perfusion, improving nutrition 58 
and the treatment of clinical infection.
2,16
 Topical treatments are widely used to treat PIs, there are a 59 
plethora of options to choose from including alginate, hydrocolloid, protease-modulating dressings, 60 
topical agents, and other therapies. Despite this, there is paucity of evidence to facilitate decision-61 
making regarding the type of topical treatments that are the most clinically effective. This is despite 62 
many published meta-analyses examining effects of dressings, negative pressure wound therapy and 63 
topical agents on healing of PIs in mainly adult populations in care settings.
18-22
  64 
A key issue has been the statistical methods used in previous reviews of topical treatments 65 
such as hydrogel,
19
 alginate,
18
 and foam
22
 as well as other therapies such as negative pressure 66 
wound therapy
20
 which only allowed pairwise comparisons. Results from these reviews consistently 67 
reported low to very low certainty of evidence from included studies due to high risk of bias (lack 68 
of allocation concealment and blind assessment) and imprecision (small studies and incomplete 69 
reporting). More significantly, they were unable to provide clear advice on effectiveness of the 70 
topical treatment in healing PIs. While we were undertaking this project, an attempt to address this 71 
limitation via a network meta-analysis was published.
21
 However, the authors of the study were still 72 
unable to determine which topical treatments were the most likely to heal PIs because sparseness of 73 
their network led to inconclusive results.
23
 Our approach differs from the latter in several ways 74 
including in the classification of topical treatments, extent of coverage of studies and methodology 75 
used which brings much more clarity to this issue and does away with the issue of sparseness.  76 
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Methods 77 
Findings of this systematic review and meta-analysis are presented according to PRISMA 78 
reporting guidelines.
24
  79 
 80 
Search strategy 81 
The original search strategy was designed in PubMed and converted for use in the following 82 
databases using the Systematic Reviews Accelerators Polyglot Search Translation module,
25
 with 83 
no limitations on year or language: CINAHL, Embase, Web of Science, Scopus, and the Cochrane 84 
Central Register of Controlled Trials (CENTRAL). The initial search was conducted on 15
th
 85 
September 2016 and updated on 1
st 
December 2017. Search terms related to pressure injuries, 86 
pressure ulcers, topical treatment types, and outcome measurements (i.e. healing) were included. 87 
The full search strategy is shown in the supplementary material (S1). In order to achieve a 88 
comprehensive evaluation of the published evidence, the systematic search was supplemented with 89 
a forwards and backwards citation search as well as retrieving the first 20 similar articles from 90 
PubMed for each of the papers included from the searches. We sought additional papers from the 91 
reference lists of relevant meta-analyses and review papers.
16,19-21,26,27
   92 
Titles and abstracts of all papers that were extracted by the search engine were uploaded to 93 
the Rayyan platform (http://rayyan.qcri.org/) which is a web application developed by Qatar 94 
Computing Research Institute (Data Analytics).
28
 Five authors (LFK, RW, BG, SD and LT) 95 
independently screened the titles and abstracts on the Rayyan platform. Any disagreements were 96 
resolved through author consensus. Additionally, LFK and RW examined the full-text papers for 97 
eligibility against the review protocol. Disagreements were resolved through consensus and by 98 
involvement of a third author (BG).  99 
 100 
Selection criteria 101 
Eligible studies were published and unpublished randomized controlled trials (RCTs) that 102 
enrolled patients with stage 2-4 PIs and compared the effectiveness of two or more of the following 103 
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13 narrow topical treatment categories: antimicrobial, basic (i.e. gauze with normal saline), 104 
collagenase, collagen, combined treatment (i.e. when multiple active components were included), 105 
film, foam (i.e. lyofoam, polyurethane), growth factors, hydrocolloid, hydrogel, moisture retentive 106 
(i.e. calcium alginate), negative pressure, and radiant heat. These dressings were selected because 107 
they were either:1) identified in the literature as wound care products used for the treatment of PIs; 108 
2) available to clinicians for use in routine practice; 3) recommended by international clinical 109 
guidelines;
2
 or 4) under investigation as an experimental or alternative dressing for the treatment of 110 
PIs. Dressings were grouped according to their dominant element. The network using these 13 111 
narrowly defined topical treatment categories initially selected was noted to be sparse. The key 112 
issue with this is that networks that are not well connected may provide unreliable estimates and 113 
rank treatment options incorrectly and/or may lead to inconsistent ranking of the dressing when the 114 
reference category changes.  115 
For these reasons a parallel analysis using a broader classification based on mechanisms of 116 
action provided by Horn
29
 was conducted. This classification defined five dressing groups as 117 
follows: Basic wound dressing (i.e. inert materials like saline gauze), hydroactive wound dressing 118 
(i.e. hydrocolloid, hydrogel, moisture retentive dressings), foam dressing, active wound dressing 119 
(i.e. collagen, growth factors), and other wound dressing (i.e. antimicrobial, collagenase, film, 120 
negative pressure, radiant heat) to achieve a network that was not sparse. These two classifications 121 
are given in table 1.  122 
Studies were also excluded if they assessed effectiveness more than one year post-treatment 123 
or included other types of wounds (e.g. chronic wound and venous leg ulcers). Because we used a 124 
pair-wise modelling approach (described below), if studies compared an odd number of eligible 125 
treatments, we selected a pair (or multiple pairs) of treatments for inclusion in meta-analysis. In 126 
such cases, we prioritised the inclusion of treatments with the lowest dose and that are currently in 127 
widespread use for PI healing over novel treatments.   128 
 129 
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Data extraction 130 
Data extraction was performed by LFK and RW. We extracted the year and country of 131 
study; study population topical treatment names, types and schedules; sample size; number of 132 
people “healed” and “not healed” after treatment; and follow-up time. If a study compared the same 133 
intervention in both arms, it was assumed that the effect of such an intervention cancelled itself 134 
from both arms (e.g. a RCT compared hydrocolloid + hydrogel against hydrocolloid + collagen, it 135 
was considered as hydrogel compared to collagen) and dressings were classified accordingly to the 136 
remaining active ingredients.  137 
 138 
Quality assessment 139 
Quality of included studies was assessed using the Cochrane Collaboration’s tool for 140 
assessing risk of bias in randomised trials.
30
 This scale assessed studies for risk of bias using items 141 
related to random sequence generation, allocation concealment, selective reporting, blinding, 142 
incomplete data, and attrition rate (supplementary material S2). 143 
 144 
Statistical analysis 145 
We aimed to examine healing rate; that is the proportion of treated individuals whose PIs 146 
healed completely based on the cure criteria, where reported in each study. The outcome calculated 147 
for each study was the relative risk (RR) of cure following topical treatment. We used an automated 148 
generalised pair-wise modelling (GPM) framework
31
 to generate mixed treatment effects against 149 
basic dressings, currently the simplest standard treatment. This framework requires no additional 150 
assumptions other than that of transitivity, and uses an automated process to extend the previously 151 
reported Bucher method
32
 for single three-treatment loops. The method involves: (1) pooling effect 152 
sizes for direct comparisons between each combination of two treatments using meta-analysis; (2) 153 
performing indirect comparisons by automated generation of all possible closed loops of three 154 
treatments such that one is common to two studies; and (3) pooling all direct and indirect effects 155 
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using meta-analysis to give a final effect size comparing each treatment to the common comparator. 156 
To pool estimates, we used the inverse variance heterogeneity model, which uses a quasi-likelihood 157 
based variance structure without distributional assumptions and has been shown to perform better 158 
when compared to the random effects method.
33
 For comparison, all analyses were re-run using the 159 
random effects model within a multivariate frequentist framework.
34
  160 
We assessed statistical heterogeneity across pooled direct effects using Cochran’s Q and the 161 
H
 
index. The H index is the square root of H
2
, the estimated residual variance from the regression of 162 
the standardized treatment effect estimates against the inverse standard error in each direct meta-163 
analysis. H was computed as follows:  164 
   
                
         
 , 165 
where n is the number of study estimates and Q represents the Chi squared from Cochran’s Q.  166 
Transitivity across the network was assessed by examining inconsistency across the network using 167 
the weighted pooled H index (  ), which was computed from Cochran’s Q as follows: 168 
    
                     
            
 , 169 
where n is the number of estimates pooled across each comparison and s is the number comparisons 170 
(out of k) where n=1. The minimum value H or    can take is 1.      was taken to be minimal 171 
inconsistency based on our simulations in homogenous direct meta-analyses.  172 
Sensitivity analyses were performed based on restricting the network to studies that 173 
examined efficacy within 6-12 weeks and to assess the impact of the risk of bias on the results 174 
(using a quality effects model
35
). 175 
Publication bias was assessed using ‘comparison-adjusted’ funnel plots, that plots the 176 
difference of each study’s observed ln(RR) versus the comparison’s mean ln(RR) obtained from 177 
meta-analysis on the horizontal axis. In the absence of small-study effects, studies are expected to 178 
form an inverted funnel centred at zero.
36
 179 
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All analyses involved in the generalised pair-wise modelling (GPM) framework were 180 
conducted using MetaXL version 5.3 (EpiGear Int Pty Ltd.; Brisbane, Australia) developed by one 181 
of us (SD). Funnel and network plots were created in Stata version 14.1 (College Station, TX, 182 
USA). 183 
 184 
Role of funding sources 185 
This research was supported by Qatar University Internal Grant No. QUUG-CHS-CHS-186 
15\16 -1. The findings detailed herein are solely the responsibility of the authors with no 187 
interference by the funder.  188 
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Results 189 
Identified studies 190 
Database searches, forwards and backwards citation search, and retrieving the first 20 191 
similar articles from PubMed identified 2496 studies that were initially screened by title and 192 
abstract, from which 172 potentially relevant papers were selected. Of these, 44 met the inclusion 193 
criteria for the systematic review and were included in the network meta-analysis (Figure 1).  194 
 195 
Characteristics of included studies 196 
The 44 included studies were published between 1983 and 2015. Studies were conducted in 197 
Asia (2 countries [Korea and Iran], 2 studies),  North America (1 country [USA]; 21 studies), and 198 
Europe (10 countries [Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, 199 
Sweden, and UK]; 21 studies).  200 
Twenty studies had a comparison to basic dressing, and 31 studies to a hydroactive dressing; 201 
representing the two most common topical treatments. The remaining studies had a variety of 202 
topical treatment types. Complete healing was assessed at a median follow-up of 8 weeks (IQR 6.5 203 
– 13 weeks) with a range of 1.5 – 52 weeks (Table 2). 204 
 205 
Included topical treatments 206 
A total of 13 topical treatment categories and 5 dressing wound groups were included in the 207 
network meta-analyses. Topical treatments within the same category were deemed exchangeable 208 
(Table 2). Figure 2A and 2B depict the network plot showing the comparison groups for each study. 209 
  210 
Quantitative synthesis 211 
Based on 44 studies examining treatment of PIs, when basic dressing was used as the 212 
reference treatment category, all topical treatment categories were found to have a better rank than 213 
basic dressing being negative pressure, film, and combined treatment the ones with the biggest 214 
effect size. Combined treatment (RR 1.88; 95%CI 1.08-3.25) was found to be the only dressing 215 
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category to have statistically significant improvement in healing when compared to basic dressings 216 
(Figure 3A). When hydrocolloid was used as the reference category in the analysis, the ranking of 217 
the dressing categories dramatically changed (Figure 3B). It is clear from the results that the 218 
network with 13 dressing categories was sparse, the point estimates were not reliable, and the 219 
ranking of the treatments was not stable. This analysis was not informative and therefore we 220 
proceeded with the next analysis. 221 
When the analysis was carried-out using the 5 wound dressing groups as defined by Horn;
29
 222 
40 studies were included, 4 studies
37-40
 were excluded because they compared wound dressings 223 
within the same group. The basic wound dressings was used as the reference group, all dressings 224 
groups were better in rank than basic dressings. In ascending order of efficacy based on the point 225 
estimate, the ranking was other, hydroactive, active, and foam dressings and only the latter being 226 
statistically significantly better (Figure 4A). The ranking of dressing groups remained unchanged 227 
when the hydroactive dressings was used as the reference (Figure 4B and supplementary material 228 
S3) revealing a stable (non-sparse) network with reliable results.  229 
Analysis using a conventional approach (i.e. multivariate frequentist framework) did not 230 
alter the ranking nor the pooled estimates significantly, but differed in terms of error estimation 231 
(confidence intervals) (supplementary material S4).  232 
 233 
Sensitivity analysis and assessment of bias 234 
Sensitivity analysis restricting the network to studies that assessed healing between 6-12 235 
weeks after treatment (n=28), showed that the results remain robust to these changes in the selection 236 
criteria revealing that foam, active wound dressing, and hydroactive wound dressing are the only 237 
treatment options (supplementary material S5).  238 
The most common deficiencies in safe-guarding against bias were: participants and 239 
personnel not blind to study group allocation (6 studies) or not clearly stated (354 studies); 240 
allocation concealment not properly conducted (4 studies) or not stated (32 studies); and outcome 241 
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assessors not blind to study group allocation (6 studies), or not stated (26 studies) (supplementary 242 
material S2). Results after application of the quality effects model
35
 were not different to the main 243 
results (supplementary material S6). 244 
Comparison-adjusted funnel plots (supplementary material S7) demonstrated little evidence 245 
of asymmetry. There was minimal inconsistency across treatment networks, with   = 1.20. There 246 
was little inconsistency across direct and indirect effects (H<3.0) for each of the treatment 247 
comparison pairs, including when the network was restricted in sensitivity analyses.   248 
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Discussion 249 
The results of the network meta-analysis that included 40 RCTs involving 1,757 250 
participants, comparing five dressing groups revealed that foam and active dressings are the most 251 
effective treatments for healing PIs. While the effect size of all dressing groups was higher than 252 
basic wound dressings, the uncertainty was also high, which means that these results need 253 
confirmation. 254 
A major issue in the recent network meta-analysis may have been the approach the 255 
researchers used to grouping PI topical treatments leading to a sparse network,
23
 and we avoided 256 
this by creating groups of tentatively similar mechanisms of action. Another key strength of the 257 
current study is the use of the GPM framework which does not require assumptions that are not 258 
stated explicitly or cannot be verified when the method is applied. In comparison, the multivariate 259 
frequentist framework commonly used in other network meta-analyses
21
 assumes that if there is no 260 
common comparator in the network, this then has to be handled by augmenting the dataset using 261 
fictional arms with high variance. This requires a decision as to what constitutes a sufficiently high 262 
variance and therefore may not always be impartial.
41
 Additionally, the GPM framework has fewer 263 
assumption (i.e. transitivity and independence of treatment effects between studies) than the 264 
multivariate frequentist framework that also requires distributional assumptions as well as 265 
augmented datasets (using fictional study arms of high variance) when studies lack the reference 266 
treatment.
34
 267 
The absence of robust research in this area and the extensive heterogeneity of dressings 268 
makes it difficult for researchers to provide clear advice to clinicians and decision-makers about 269 
safe and effective PI treatment options for patients. While the findings from our analysis contribute 270 
to decision-making related to choice of therapy, topical treatments, they should be considered 271 
carefully. Given the huge variety of treatment options now available within the health industry, 272 
clinicians should also consider contextual factors such as wound characteristics, patient preference 273 
and cost. However, the results of this study do indicate that basic dressings should be abandoned in 274 
favor of the better options in terms of wound healing. 275 
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Despite the methodological strengths of our study, we acknowledge some limitations. 276 
Firstly, the topical treatments included in the designated categories may have been developed by 277 
different manufacturers, had slightly different compositions, and had variation in duration of 278 
interventions between studies. Additionally, the assumption of exchangeability within category was 279 
an empirical judgement and should be considered a limitation of this network meta-analysis. 280 
Secondly, the network meta-analysis only focused on complete wound healing. Other outcomes 281 
such as time to complete healing, reduction in ulcer size, adverse events, cost, and patient quality of 282 
life should also be considered in future analyses. 283 
 284 
Conclusion 285 
Findings from this systematic review and network meta-analysis demonstrate evidence for 286 
the discontinuation of use of basic dressings. Hydroactive dressings are the mainstay practice, but 287 
our analysis suggests that the use of foam or active wound dressings may be more effective 288 
strategies for healing PIs. This should not be considered conclusive and more high-quality, rigorous 289 
research about the effectiveness of the dressings within these two groups is needed to confirm if 290 
these are indeed better than the current standard of hydroactive dressings.   291 
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Figures titles 506 
 507 
Figure 1. PRISMA flow diagram of study selection for quantitative synthesis 508 
 509 
Figure 2. Network plot showing the A) 13 topical treatment categories and B) 5 wound dressing 510 
groups. The circle size is proportional to the number of arms while the width of the lines is 511 
proportional to the number of pairs. 512 
 513 
Figure 3. Network forest plot baseds on 44 studies ranking comparisons based on their relative risk 514 
for wound healing using A) basic and B) hydrocolloid as the reference topical treatment category. 515 
When the reference treatment category changes, the ranking changes as well due to sparseness in 516 
the network making these results unreliable. 517 
 518 
Figure 4. Network forest plots based on 40 studies ranking comparisons based on their relative risk 519 
for wound healing using A) basic and B) hydroactive as the reference dressing group. This network 520 
is non-sparse and stable, thus rankings remain reliable when the reference dressing group changes.  521 
 522 
  523 
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Table 1.  Classification of the dressings 524 
Topical treatment categories Wound dressing groups Description 
BAS Basic (e.g. saline gauze, 
placebo) 
BWD Basic Inactive dressings can pick up 
secretions from the wound, but do 
not create a specific 
microenvironment that promotes 
wound healing. 
HCD Hydrocolloid (e.g. DuoDerm, 
Comfeel Plus, Tegaderm) 
HWD Hydroactive Hydroactive wound dressings 
accelerate wound healing by 
altering the microclimate of the 
wound and imitating the 
physiological process to form a 
moist wound environment. 
HGD Hydrogel (e.g. Askina 
Transorbent, BioFilm hydrogel, 
Acemannan hydrogel) 
MRD Moisture retentive (e.g. 
UrgoSorb, Aquacel) 
FOA  Foam (e.g. Epi-Lock dressing, 
Allevyn hydrocellular foam, 
Spyrosorb) 
FOA Foam Foam dressings absorb wound 
exudate, insulate the wound and 
provide a moist wound healing 
environment. 
COL Collagen (e.g. Promogran, 
Medifil Collagen Particles) 
AWD Active Active dressings have a defined 
mechanism of action through which 
they intervene in the patho-
physiological processes in the 
wound by substitution / suppression 
or alteration of factors. 
GRF Growth factor (e.g. Dermagraft, 
Transforming growth factor 
beta-3, Recombinant platelet-
derived growth factor-BB) 
AMD Antimicrobial (e.g. Cadexomer 
iodine, povidine soaked wet 
gauze, Dakin's solution) 
OWD Other Wound dressings with other 
mechanisms of action. 
CLD Collagenase (e.g. Iruxol mono 
ointment) 
FIL Film (e.g. 3M Tegaderm 
Absorbent Clear Acrylic 
Dressing) 
NPD Negative pressure (e.g. V.A.C. 
therapy system) 
RHD Radiant heat (e.g. Augustine 
Medical warm-up) 
COM Combined – multiple active 
compoenents 
Classified in a dressing group depending on the type of 
combination of the active ingredients. 
 
- Topical treatment categories: AMD antimicrobial; BAS basic; CLD collagenase; COL collagen; COM combined 
treatment; FIL film; FOA foam; GRF growth factor; HCD hydrocolloid; HGD hydrogel; MRD moisture retentive; 
NPD negative pressure; RHD radiant heat. 
- Wound dressing groups: AWD active; BWD basic; FOA foam; HWD hydroactive; OWD other wound dressing. 
 525 
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Table 2. Characteristics of the included studies 
 
Serial 
number 
First author and year 
of publication 
Study 
location 
Follow-up 
duration 
Topical treatments 
Topical 
treatment 
category 
Wound 
dressing 
group 
Number of 
participants 
(healed/ 
treated) 
Criteria for complete healing 
1 Alm (1989)42 Sweden 6 weeks 
- Hydrocolloid 
- Saline gauze 
HCD 
BAS 
HWD 
BWD 
17/31 
4/25 
Area of the PI equal to zero 
2 
Anguilo-Sanchez 
(2001)43 
Spain  7 weeks 
- Alginate and hydrocolloid 
- Saline gauze 
COM 
BAS 
HWD 
BWD 
20/35 
10/35 
Not reported  
3 Ashby (2012)44 UK 26 weeks 
- Hydrocolloid, alginate 
- Negative pressure dressing 
COM 
NPD 
HWD 
OWD 
0/6 
1/6 
Epithelialisation and cessation 
of treatment to achieve healing 
4 Bale (1997)45 UK 4 weeks 
- Polyurethane foams 
- Hydrocolloid 
FOA 
HCD 
FOA 
HWD 
7/29 
5/31 
Not reported  
5 Banks (1994a)46 UK 6 weeks 
- Semi-permeable polyurethane dressing 
- Hydrocolloid 
FOA 
HCD 
FOA 
HWD 
11/13 
10/16 
Not reported 
6 Banks (1994b)47 UK 12 weeks 
- Polyurethane dressing 
- Hydrocolloid 
FOA 
HCD 
FOA 
HWD 
12/20 
10/20 
Not reported 
7 Belmin (2002)48* France 8 weeks 
- Hydrocolloid 
- Calcium alginate and hydrocolloid 
BAS 
MRD 
BWD 
HWD 
31/53 
43/57 
Surface area reduction ≥40%  
8 Brod (1990)37† USA 8 weeks 
- Polyhema dissolved in polyethylene glycol 
- Hydrocolloid 
HGD 
HCD 
HWD 
HWD 
14/27 
10/16 
Not reported 
9 Brown-Etris (1996)38† USA 10 weeks 
- Hydrogel 
- Hydrocolloid 
HGD 
HCD 
HWD 
HWD 
39/77 
37/77 
Not reported 
10 Brown-Etris (2008)49 USA 8 weeks 
- Hydrocolloid 
- Transparent absorbent acrylic 
HCD 
FIL 
HWD 
OWD 
22/37 
21/35 
Closed PI wounds 
11 Burgos (2000)50 Spain 12 weeks 
- Hydrocolloid 
- Collagenase ointment 
HCD 
CLD 
HWD 
OWD 
3/19 
3/18 
PI with final surface area of 
zero 
12 Colwell (1993)51 USA 12 weeks 
- Hydrocolloid wafer dressing 
- Saline gauze 
HCD 
BAS 
HWD 
BWD 
11/33 
1/37 
PI completely covered with 
epithelial tissue 
13 Darkovich (1990)39† USA 8.5 weeks 
- Hydrocolloid 
- Biofilm hydrogel 
HCD 
HGD 
HWD 
HWD 
9/36 
12/35 
PI wound closure 
14 Ford (2002)52 USA 6 weeks 
- Vaccum assisted closure 
- Healthpoint system 
NPD 
COM 
OWD 
HWD 
2/20 
2/15 
Not reported 
15 Gorse (1987)53 USA 11 weeks 
- Hydrocolloid 
- Wet-to-dry dressing with Dakin solution 
HCD 
AMD 
HWD 
OWD 
54/76 
26/52 
Not reported 
16 Graumlich (2003)54 USA 8 weeks 
- Hydrocolloid 
- Collagen 
HCD 
COL 
HWD 
AWD 
15/30 
18/35 
Not reported 
17 Hirshberg (2001)55# USA 16 weeks 
- TGF-b3 1 ug/cm2 
- TGF-b3 2.5 ug/cm2 [excluded arm] 
- Placebo gel 
GRF 
- 
BAS 
AWD 
- 
BWD 
0/4 
- 
0/5 
Not reported 
25 
 
18 Hollisaz (2004)56
¶
 Iran 8 weeks 
- Hydrocolloid 
- Saline gauze 
- Phenytoin cream [excluded arm] 
HCD 
BAS 
- 
HWD 
BWD 
- 
12/18 
3/19 
- 
Intact dermis and epidermis, no 
abrasion or ulceration. 
19 Kim (1996)57 Korea 7.6 weeks 
- Hydrocolloid 
- Wet-to-dry dressing with povidone iodine 
HCD 
AMD 
HWD 
OWD 
21/26 
14/18 
When no further dressing was 
required 
20 Kraft (1993)58 USA 24 weeks 
- Saline gauze 
- Epi-lock dressing 
BAS 
FOA 
BWS 
HWS 
3/14 
10/24 
Not reported 
21 Kuflik (2001)59& USA 6 weeks 
- ResurfixR 
- Petrolatum jelly 
COM 
BAS 
AWD 
BWD 
2/5 
0/3 
Not reported 
22 Landi (2003)60 Italy 6 weeks 
- Topical nerve growth factor 
- Balanced salt solution 
GRF 
BAS 
AWD 
BWD 
8/18 
1/18 
Not reported 
23 Matzen (1999)61 Denmark 12 weeks 
- Saline gauze 
- Hydrocolloid 
BAS 
HCD 
BWD 
HWD 
0/15 
5/17 
Not reported 
24 Moberg (1983)40† Sweden 8 weeks 
- Saline, enzyme debriding, or nonadhesive dressing 
- Cadexomer iodine 
COM 
AMD 
OWD 
OWD 
1/18 
6/16 
Not reported 
25 Muller (2001)62 Netherlands  14 weeks 
- Collagenase ointment 
- Hydrocolloid 
CLD 
HCD 
OWD 
HWD 
11/12 
7/11 
Total epithelialization of PIs 
26 Mustoe (1994)63^ USA 26 weeks 
- rPDGF-BB 100 ug/ml 
- rPDGF-BB 300 ug/ml [excluded arm] 
- Placebo - Growth factor excluded 
GRF 
- 
BAS 
AWD 
- 
BWD 
2/15 
- 
1/14 
Area of opening being equal to 
zero 
27 Neill (1989)64 USA 8 weeks 
- Hydrocolloid 
- Saline gauze 
HCD 
BAS 
HWD 
BWD 
13/42 
10/45 
Not reported 
28 Nisi (2005)65 Italy 26 weeks 
- Povidone iodine plus paraffin 
- Protease modulating matrix 
AMD 
COL 
OWD 
AWD 
28/40 
36/40 
Not reported 
29 Oleske (1986)66 USA 1.5 weeks 
- Polyurethane self-adhesive foam dressing 
- Saline gauze 
FOA 
BAS 
HWD 
BWD 
0/5 
0/5 
Not reported  
30 Payne (2001)67¥  USA 52 weeks 
- GM-CSF 
- Placebo 
- bFGF [excluded arm] 
- Sequential GM-CSF and bFGF [excluded arm] 
GRF 
BAS 
- 
- 
AWD 
BWD 
- 
- 
12/15 
10/15 
- 
- 
Wound closure ≥85% 
31 Payne (2004)68 USA 24 weeks 
- Saline gauze 
- Dermagraft 
BAS 
GRF 
HWD 
AWD 
2/16 
2/18 
Full epithelialization and the 
absence of drainage 
32 Payne (2009)69 USA 4 weeks 
- Self-adhesive polyurethane foam dressing 
- Saline gauze 
FOA 
BAS 
HWD 
BWD 
10/20 
6/16 
Not reported 
33 Piatkowski (2012)70§ Germany 3 weeks 
- Polyurethane foam dressing + Collagen 
- Polyurethane foam dressing 
COL 
BAS 
AWD 
BWD 
5/5 
4/5 
Not reported 
34 Price (2000)71 UK 6 weeks 
- Alginates 
- Radiant heat dressing 
MRD 
RHD 
HWD 
OWD 
2/25 
3/25 
Not reported  
35 
Ramos-Torrecillas 
(2015)72£ 
Spain 5 weeks 
- Saline gauze 
- PRGF 
- 2 doses of PRGF [excluded arm] 
- PRGR + hyaluronic acid [excluded arm] 
BAS 
GRF 
- 
- 
HWD 
AWD 
- 
- 
0/25 
3/34 
- 
- 
Total closure of the PI  
26 
 
36 Rees (1999)73‡ USA 16 weeks 
- Saline gauze 
- Becaplermin gel 100 ug/g only 
- Becaplermin gel 100 ug/g alternated with placebo 
[excluded arm] 
- Becaplermin gel 300 ug/g alternated with placebo 
[excluded arm] 
BAS 
GRF 
- 
- 
BWD 
AWD 
- 
- 
0/31 
7/31 
- 
- 
 
100% healed PIs 
37 Scevola (2010)74 Italy 14 weeks 
- Allogenic platelet gel 
- Standard treatment 
GRF 
COM 
AWD 
HWD 
0/8 
0/8 
Not reported 
38 Sebern (1986)75 USA 8 weeks 
- Moisture vapour permeable dressing 
- Wet-to-dry gauze 
FIL 
BAS 
OWD 
BWD 
14/22 
0/12 
Not reported 
39 Seeley (1999)76 USA 8 weeks 
- Hydrocolloid 
- Hydrocellular foam 
HCD 
FOA 
HWD 
FOA 
8/19 
8/20 
Closed PI 
40 Sipponen (2008)77 Finland 26 weeks 
- Sodium carboxymethylcellulose hydrocolloid 
polymer 
- Resin salve of the Norway spruce 
MRD 
AMD 
HWD 
OWD 
4/9 
12/13 
Not reported 
41 Sopata (2002)78 Poland 8 weeks 
- Lyofoam 
- Hydrogel 
FOA 
HGD 
FOA 
HWD 
15/18 
15/20 
Closed PI wounds 
42 Thomas (1998)79 UK 10 weeks 
- Acermannan hydrogel 
- Saline gauze 
HGD 
BAS 
HWD 
BWD 
10/16 
9/14 
Not reported 
43 Thomas (2005)80 UK 12 weeks 
- Hydrocolloid 
- Radiant heat dressing 
HCD 
RHD 
HWD 
OWD 
7/20 
8/21 
Not reported 
44 Xakellis (1992)81 USA 10 weeks 
- Hydrocolloid 
- Saline gauze 
HCD 
BAS 
HWD 
BWD 
16/18 
18/21 
PI had epithelial covering 
* Belmin (2002): Both intervention arms received hydrocolloid, the effect of hydrocolloid cancels and the comparison will be saline (BAS) versus calcium alginate (MRD). 
#
 Hirshberg (2001): Contains three internvention arms (2 active [GRF] and 1 control [BAS]), the active arm with the lowest dose and the control were included in the analysis. 
¶
 Hollisaz (2004): Contains three intervention arms, phenytoin cream was excluded from the analysis as it does not fit in any of the pre-specified dressing categories. 
&
 Kuflik (2001): Both intervention arms contain petrolatum, the effect of petrolatum jelly cancels and the comparison will be saline (BAS) versus combine treatment (COM). 
^ Mustoe (1994): Contains three internvention arms (2 active [GRF] and 1 control [BAS]), the active arm with the lowest dose and the control were included in the analysis. 
¥ 
Payne (2001): Contains four internvention arms (3 active [GRF] and 1 control [BAS]), the active arm with the GM-CSF and the control were included in the analysis. 
§ Piatkowski (2012): Both intervention arms recevied foam dressing, the effect of foam dressing cancels and the comparison will be saline (BAS) versus collagen (COL). 
£ Ramos-Torrecilla (2015): Contains four internvention arms (3 active [GRF] and 1 control [BAS]), the active arm with the lowest dose and the control were included in the analysis. 
‡ Rees (1999): Contains four internvention arms (3 active [GRF] and 1 control [BAS]), the active arm with the lowest dose and the control were included in the analysis. 
 
†
 Brod (1990), Brown-Etris (1996), Darkovich (1990), Moberg (1983) excluded from the analysis using the 5 dressing groups. 
 
- Topical treatment categories: AMD antimicrobial; BAS basic; CLD collagenase; COL collagen; COM combined treatment; FIL film; FOA foam; GRF growth factor; HCD hydrocolloid; HGD 
hydrogel; MRD moisture retentive; NPD negative pressure; RHD radiant heat. 
- Dressing wound groups: AWD active; BWD basic; FOA foam; HWD hydroactive; OWD other wound dressing.  
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Figure 1. PRISMA flow diagram of study selection for quantitative synthesis. 
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Figure 2. Network plot showing the A) 13 topical treatment categories and B) 5 wound dressing groups. The circle size is proportional to the 
number of arms while the width of the lines is proportional to the number of pairs. 
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Figure 3. Network forest plot baseds on 44 studies ranking comparisons based on their relative risk for wound healing using A) basic and B) 
hydrocolloid as the reference topical treatment category. When the reference treatment category changes, the ranking changes as well due to 
sparseness in the network making these results unreliable.  
 
AMD antimicrobial; BAS basic; CLD collagenase; COL collagen; COM combined treatment; FIL film; FOA foam; GRF growth factor; HCD hydrocolloid; 
HGD hydrogel; MRD moisture retentive; NPD negative pressure; RHD radiant heat  
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Figure 4. Network forest plots based on 40 studies ranking comparisons based on their relative risk for wound healing using A) basic and B) 
hydroactive as the reference dressing group. This network is non-sparse and stable, thus rankings remain reliable when the reference dressing 
group changes.  
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